secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001831283-23-000071
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio's mavacamten meets primary endpoint in Phase 3 EXPLORER-CN trial; NDA accepted with Priority Review in China
--------------------------------------------------------------------------------

- EXPLORER-CN met primary endpoint: Valsalva LVOT gradient improvement from baseline to week 30 vs placebo (p<0.001).
- All secondary endpoints met, including resting LVOT gradient, NYHA class improvement, KCCQ-CSS, and LV mass index.
- Safety consistent with prior studies; no LVEF <50% requiring dose interruption.
- NDA for mavacamten accepted with Priority Review by China NMPA for symptomatic oHCM.
- LianBio to host analyst event May 1 to discuss topline data and China market opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000071/0001831283-23-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000071/lian-20230426.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer